Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers? If so, then you’ll definitely want to add Kazia Therapeutics (NASDAQ: KZIA ) to your watch list. I can’t guarantee any safety whatsoever, but Kazia Therapeutics stock offers excitement and the possibility of substantial profits. Or, Kazia Therapeutics might not secure full regulatory approval for its primary product, and the stock could go nowhere or just go to zero.
Nearly any outcome is plausible in the wild world of biotech stocks . So, I invite you to discover Kazia Therapeutics and decide if your stomach can handle the volatility and unpredictability. Why Kazia Therapeutics Stock Went Bananas Just to recap, Australian biotechnology business Kazia Therapeutics develops oncology (cancer and tumor fighting) drugs.
One of Kazia Therapeutics’ drug-development programs is EVT801 . This was found in preclinical research to be “active against a broad range of tumour types.” Not to discount the importance of EVT801, but Kazia Therapeutics’ primary drug in development is paxalisib .
Recently, Kazia Therapeutics completed a phase II/III study of paxalisib in the treatment of a type of brain cancer type called glioblastoma. Kazia Therapeutics CEO John Friend proudly announced the results of the clinical trial. Paxalisib demonstrated a “3.
8 month improvement in overall survival, an approximate 33% improvement” for selected glioblastoma patients when.